Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Beauvais

Showing results (31-40 of 34) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 34 results.
Biophysical Journal|December 1, 1996
Formation of an active dimer during storage of interleukin-1 receptor antagonist in aqueous solutionB S Chang, R M Beauvais, T Arakawa, et al.
The FEBS Journal|January 22, 2013
Vascular endothelial-cadherin stimulates syndecan-1-coupled insulin-like growth factor-1 receptor and cross-talk between αVβ3 integrin and vascular endothelial growth factor receptor 2 at the onset of endothelial cell dissemination during angiogenesisAlan C Rapraeger, Brian J Ell, Madhuchhanda Roy, et al.
Signal Transduction and Targeted Therapy|May 11, 2026
SSTN<sub>IV</sub>, a syndecan-1-targeting peptide chimera, reverses immune suppression and inhibits myeloma progressionOisun Jung, DeannaLee M Beauvais, Gavril L Ibaan, et al.
Healthcare (Basel, Switzerland)|June 2, 2021
Exploring Health Outcomes for U.S. Veterans Compared to Non-Veterans from 2003 to 2019Jose A Betancourt, Paula Stigler Granados, Gerardo J Pacheco, et al.
Pageof 4

Showing results (31-40 of 34) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 34 results.
Biophysical Journal|December 1, 1996
Formation of an active dimer during storage of interleukin-1 receptor antagonist in aqueous solutionB S Chang, R M Beauvais, T Arakawa, et al.
The FEBS Journal|January 22, 2013
Vascular endothelial-cadherin stimulates syndecan-1-coupled insulin-like growth factor-1 receptor and cross-talk between αVβ3 integrin and vascular endothelial growth factor receptor 2 at the onset of endothelial cell dissemination during angiogenesisAlan C Rapraeger, Brian J Ell, Madhuchhanda Roy, et al.
Signal Transduction and Targeted Therapy|May 11, 2026
SSTN<sub>IV</sub>, a syndecan-1-targeting peptide chimera, reverses immune suppression and inhibits myeloma progressionOisun Jung, DeannaLee M Beauvais, Gavril L Ibaan, et al.
Healthcare (Basel, Switzerland)|June 2, 2021
Exploring Health Outcomes for U.S. Veterans Compared to Non-Veterans from 2003 to 2019Jose A Betancourt, Paula Stigler Granados, Gerardo J Pacheco, et al.
Pageof 4